Antibacterial drug discovery: is it all downhill from here?
about
Targeting antibacterial agents by using drug-carrying filamentous bacteriophagesStrategies to minimize antibiotic resistanceCombating antimicrobial resistance: policy recommendations to save livesIdentification of novel antimicrobials using a live-animal infection modelChallenges of antibacterial discoveryThe future of antibioticsFinding alternatives to antibiotics.A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa VirulenceSmall molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria.Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012.The sociomicrobiology of antivirulence drug resistance: a proof of conceptIdentification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.Neomycin Sulfate Improves the Antimicrobial Activity of Mupirocin-Based Antibacterial Ointments.Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureusAntimicrobial resistance determinants and future control.Do physiological roles foster persistence of drug/multidrug-efflux transporters? A case study.Antibiotic resistance - why is the problem so difficult to solve?Novel approaches to developing new antibiotics for bacterial infections.Inhibitors of reactive oxygen species accumulation delay and/or reduce the lethality of several antistaphylococcal agents.Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents.The FDA reboot of antibiotic development.High-throughput screen for novel antimicrobials using a whole animal infection model.Bacteriophage and their lysins for elimination of infectious bacteria.Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumoniaDiscovery and development of lantibiotics; antimicrobial agents that have significant potential for medical application.Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.Nanosilver-based antibacterial drugs and devices: mechanisms, methodological drawbacks, and guidelines.Genomic tools to profile antibiotic mode of action.An array of Escherichia coli clones over-expressing essential proteins: a new strategy of identifying cellular targets of potent antibacterial compounds.A screen for kinase inhibitors identifies antimicrobial imidazopyridine aminofurazans as specific inhibitors of the Listeria monocytogenes PASTA kinase PrkA.Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.In vitro activity of novel in silico-developed antimicrobial peptides against a panel of bacterial pathogens.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Bacterial fitness shapes the population dynamics of antibiotic-resistant and -susceptible bacteria in a model of combined antibiotic and anti-virulence treatment.The antibiotic pipeline: reviving research and development and speeding drugs to market.Antimicrobial resistance: A global emerging threat to public health systems.Patterns of Multi-Antibiotic-Resistant Escherichia Coli from Streams with No History of Antimicrobial Inputs.An integrated microfluidic platform for evaluating in vivo antimicrobial activity of natural compounds using a whole-animal infection model.
P2860
Q24548258-D4EC010E-EC2C-4564-9D74-2900C63224D3Q24607946-EB2C7E6D-FEDE-4E81-82B7-5A21F9188C24Q24632857-83E6C620-6669-4C98-9994-C9EB3DA41BB0Q33248011-ABD68DED-9BE1-466A-BABC-992B6EEB23A6Q33793074-65CAB775-A270-4B39-90C5-0FB320087297Q33821520-76ADFB37-5F7E-4485-9362-4ABE311A7408Q34426004-20BA730C-7907-4341-9F3A-4A2969CBE8B7Q34539031-1C5DB170-32B7-44D3-B2F6-22A3C3FD969CQ34582921-C8E55A8B-EDD8-4993-838B-5D295657B509Q35015321-50678D15-7603-42AF-94AD-D8293E926257Q35305621-B6252D1B-D182-4147-8494-B8EB30D954F0Q35805321-18F15384-341C-4CC6-AF5B-76F6008FDBFBQ35848987-A3C4CEB1-5D56-4BAE-A168-DA0C15FD07A8Q35850231-EEEA7A1D-CE26-41AF-B1D9-17764A724F8DQ36009380-027EA58B-EAD8-40A9-B82B-4BA2C3B2F385Q36161983-D37D9541-BDBA-4133-B8F0-A019C815E940Q36185086-417C4373-3538-4BCF-BB99-1D919A5A9BF4Q36358643-012A2E7E-896A-4876-8CE8-A2386E758E43Q36364252-5C1D6293-6B7C-4EA0-8A12-516EE1B88908Q36802598-651AD04A-D4F9-4AF6-B454-C8058BB882DCQ37263756-ADE8C234-7080-4A65-A946-DD8A6D539551Q37350471-61DE68AC-D366-43D8-BE0C-057E87E91B3EQ37470848-C58B8351-8BEB-49A4-ACCD-4778FED789CCQ37544870-C07CE4E6-CD11-40B4-9F4F-A08A4A17DC10Q38014580-F5ABF7D9-D421-4083-BD87-77373C1B7422Q38137920-51AE4A3D-9519-4727-85C2-BDC7C6961F2DQ38167600-138F8E2C-A07F-48E7-AAD5-97D05772CCD7Q38195069-CFCCFEE7-8C91-46FF-80D4-7920DBA50448Q38505082-D313DC29-855F-46CF-8494-1CD85259D37EQ38618015-CDAA8381-B9BD-4748-A389-5E12BDFF92C8Q38793981-CB71DF3F-7F61-489D-9A0D-0D7149B193B7Q39119164-E005491E-0F8C-4E47-92BC-6DC02514E931Q39120027-72E9718E-4AC3-4CA7-BD5F-71C252BE5784Q39626504-CED08A86-7ECF-4719-A645-71FB1C5D9A50Q40290086-21C4FB57-76B5-453B-8CCB-E13A7F51B17EQ41225485-DA278356-F661-4EE3-8ABA-B0E91C07E797Q48276953-6DC929D7-FB19-4B9F-B3EB-C1F95A185B47Q51530334-316EA6EB-0603-4079-A32E-F2FDB9C7EA5B
P2860
Antibacterial drug discovery: is it all downhill from here?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Antibacterial drug discovery: is it all downhill from here?
@ast
Antibacterial drug discovery: is it all downhill from here?
@en
type
label
Antibacterial drug discovery: is it all downhill from here?
@ast
Antibacterial drug discovery: is it all downhill from here?
@en
prefLabel
Antibacterial drug discovery: is it all downhill from here?
@ast
Antibacterial drug discovery: is it all downhill from here?
@en
P1476
Antibacterial drug discovery: is it all downhill from here?
@en
P2093
P356
10.1111/J.1465-0691.2004.1006.X
P478
10 Suppl 4
P577
2004-11-01T00:00:00Z